Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Reata Pharma (NQ: RETA )

30.54 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 28, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 30.54
Bid (Size) 22.65 (1)
Ask (Size) 49.50 (5)
Prev. Close 30.54
Today's Range 30.54 - 30.54
52wk Range 20.23 - 153.41
Shares Outstanding 36,321,351
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Reata Pharmaceuticals Earnings Perspective: Return On Capital Employed
According to data from Benzinga Pro, during Q1, Reata Pharmaceuticals's (NASDAQ:RETA) reported sales totaled $914.00 thousand. Despite a 13.52% increase in earnings, the company posted a loss of $73.84... 
Via Benzinga
Where Reata Pharmaceuticals Stands With Analysts
Over the past 3 months, 4 analysts have published their opinion on Reata Pharmaceuticals (NASDAQ:RETA) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga

Performance

YTD
+12.35%
+12.35%
1 Month
+7.99%
+7.99%
3 Month
-11.58%
-11.58%
6 Month
+16.92%
+16.92%
1 Year
-79.81%
-79.81%

More News

Read More
Pharma Stock Shoots Up As FDA Accepts NDA For Neuromuscular Disorder Drug Under Priority Review
Via Benzinga
The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review
Via Benzinga
Reata Pharmaceuticals Announces FDA Filing Acceptance and Priority Review Designation for the NDA for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia
From Reata Pharmaceuticals, Inc.
Via Business Wire
Recap: Reata Pharmaceuticals Q1 Earnings
Via Benzinga
NASDAQ:RETA Long Term Shareholder Notice: Investigation over Possible Wrongdoing at Reata Pharmaceuticals, Inc.
Via SBWire
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Via Benzinga
Reata Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs
From Reata Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For May 10, 2022
Via Benzinga
Reata Pharmaceuticals Earnings Preview
Via Benzinga
Reata Pharmaceuticals, Inc. to Report First Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on May 10, 2022
From Reata Pharmaceuticals, Inc.
Via Business Wire
Reata Stock Enjoys A Two-Day Climb — Why It Could Still Be Facing Everest
Via Investor's Business Daily
The Daily Biotech Pulse: SELLA In-licenses Oncology Asset, Merck's Pneumococcal Vaccine Review Extended, Arc Biopharma COVID Drug Flunks Mid-Stage Study
Via Benzinga
Reata Pharmaceuticals Completes Rolling Submission of New Drug Application for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia
From Reata Pharmaceuticals, Inc.
Via Business Wire
50 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
35 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2022
Via Benzinga
Regulus Moving Closer To Potential $25 Million Milestone Payment For Novel Kidney Disease Treatment Licensed To Sanofi
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
Via Benzinga
Reata Pharmaceuticals's Return on Invested Capital Insights
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
67 Biggest Movers From Yesterday
Via Benzinga
42 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.